Type 1 diabetes prevention: Insulin vaccine undergoes second trial

The insulin vaccination trial is a prime example of the excellent cooperation between universities and research institutes. Participants in the study are the Institute of Diabetes Research at the Helmholtz Zentrum München, the Paul Langerhans Institute Dresden at the Technische Universität Dresden, the German Center for Diabetes Research (DZD), the Technical University of Munich (TUM) and the Ludwig Maximilians University of Munich (LMU).

The new Pre-POINTearly vaccination study will treat children between the ages of six months and two years who carry a genetic risk of developing type 1 diabetes or have a family history of the disease, but who have not yet developed an autoimmune response. As in the preceding Pre-POINT study, the participants will take the insulin in powder form with their food every day for twelve months. The daily dose will be gradually increased from 7.5 mg to 67.5 mg. Medical examinations will be conducted at three-month intervals in order to monitor the general health of the participants. In the preceding study, oral insulin was shown to be well tolerated and safe. Hypoglycemia or other adverse effects such as allergies did not occur.

Why oral insulin as a vaccine?

When insulin is given orally, it is absorbed through the mucous membranes of the mouth and the intestines, and is split into smaller components during the digestive process. That is why oral insulin -- in contrast to insulin that is injected -- has no influence whatsoever on blood sugar levels. Instead it acts like a vaccine that trains the immune system. "The autoimmune response that causes type 1 diabetes in childhood is often initially directed at the insulin," explains Prof. Anette-Gabriele Ziegler, Director of the Institute of Diabetes Research. The aim of the Pre-POINTearly study is therefore to build up immune tolerance to insulin and thus block the autoimmune process." It is hoped that insulin in powder form will stimulate the growth of protective immune cells and thus prevent the destruction of beta cells.

The working group headed by Professor Joerg Hasford of the Institute for Medical Information Processing, Biometrics and Epidemiology at LMU Munich is responsible for the methodology, data coordination and statistical evaluation of the Pre-POINT and Pre-POINTearly studies.